Top

Advances in Therapy

Published in:

Open Access 01-12-2013 | Letter from the Editor

“All I want for Christmas is Two”: The Advent of Novel Fixed-Combination Inhalers for COPD and Outlook for 2014

Author: Kai M. Beeh

Published in: Advances in Therapy | Issue 12/2013

Excerpt

Dear Colleague, …

Theravance^®. BREO^® ELLIPTA™ Now available in the US for the treatment of COPD. Available at: http://investor.theravance.com/releasedetail.cfm?ReleaseID=801611. Last accessed November 15, 2013.

Novartis. Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan. Available at: www.novartis.com/newsroom/media-releases/en/2013/1730580.shtml. Last accessed November 15, 2013.

Theravance^®. FDA Advisory Committee Recommends Approval in US of umeclidinium/vilanterol for the treatment of COPD. Available at http://investor.theravance.com/releasedetail.cfm?ReleaseID=789930. Last accessed November 15, 2013.

Almirall. Aclidinium and formoterol fixed dose combination for COPD submitted for registration in Europe. Available at http://www.almirall.com/webcorp2/cda/comunicacion_detalle_noticia.jsp?id=2593. Last accessed November 15, 2013.

Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:347–65.PubMedCrossRef

Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–36.PubMedCentralPubMedCrossRef

Calverley PMA, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–56.PubMedCrossRef

Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1:210–23.CrossRef

Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mcg) improves lung function in COPD: a randomised trial. Respir Med. 2013;107:550–9.PubMedCrossRef

10.

Agusti A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J. 2013. doi:10.1183/09031936.00054213.

11.

Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013. doi:10.1183/09031936.00200212.

12.

Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538–46.PubMedCrossRef

13.

Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J. 2013. doi: 10.1183/09031936.00124013.

14.

Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51–60.PubMedCrossRef

15.

Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199.CrossRef

16.

Beeh KM, Korn S, Beier J, et al. QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study. Thorax 2012;67:A147 (Abstract).

17.

Maltais F, Singh SJ, Donald A, et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomized clinical trials. Eur Respir J. 2013;P761.

18.

Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42:636–46.PubMedCrossRef

19.

Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41:1017–22.PubMedCrossRef

Title: “All I want for Christmas is Two”: The Advent of Novel Fixed-Combination Inhalers for COPD and Outlook for 2014
Author: Kai M. Beeh
Publication date: 01-12-2013
Publisher: Springer Healthcare
Published in: Advances in Therapy / Issue 12/2013
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-013-0075-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2013

The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension

The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy

Retrospective Analysis of First-Line Anti-Vascular Endothelial Growth Factor Treatment Patterns in Wet Age-Related Macular Degeneration

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups

Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer

The Real-World Dose-Relativity of Sevelamer Hydrochloride and Lanthanum Carbonate Monotherapy in Patients with End-Stage Renal Disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials